Shenji Bio
Synthgene (Jiangsu Synthgene Biotechnology Co., Ltd.) is a China-based provider of nucleic acid raw materials and CRDMO services for mRNA therapeutics, oligonucleotide drugs, and molecular diagnostics, supplying GMP-grade inputs and integrated CRO services to pharmaceutical and biotech customers globally.
- Company typePrivate
- Founded2018
- HeadquartersNanjing, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Shenji Bio does
Synthgene (Jiangsu Synthgene Biotechnology Co., Ltd., branded as Shenji Bio) is a China-based provider of raw materials and contract services for nucleic acid therapeutics. Founded in 2018 in Yixing, Wuxi (Jiangsu Province), the company supplies GMP-grade and research-grade inputs used in mRNA vaccine and therapeutic manufacturing, oligonucleotide drug development, and molecular diagnostics. Its core product portfolio includes IVT enzymes and buffers, modified nucleotides, cap analogs, stock mRNA, mRNA kits, LNP delivery components, phosphoramidites (across DNA, 2'-O-Me, 2'-F, MOE, locked nucleic acid, and other modifications), nucleosides, GalNAc conjugates, succinates, phosphorus reagents, and diagnostic nucleotides. The company also operates an integrated CRDMO service platform covering sequence design, nucleic acid chemistry, IVT and LNP encapsulation, and quality testing, and offers Ab-LNP quality control using nano-flow cytometry for in vivo CAR-T applications.
The company's technology base rests on 100+ patents, including a CNIPA-granted cap analog patent (2020), a low-dsRNA T7 polymerase validated as top-performing in international third-party blind testing by UBC RNA & Formulation Core, and proprietary ionizable lipids supporting extra-hepatic delivery. Production is anchored in a 30,000 sqm GMP facility in Yixing, with a new dedicated 'chip' factory launched in 2025 for nucleic acid drug raw materials. Regulatory milestones include an FDA Type II Drug Master File for core mRNA vaccine raw materials (2022) and National SRDI 'Little Giant' Enterprise designation (2024). The company claims over 80% market coverage in human mRNA vaccines and over 90% in animal mRNA vaccines in China.
Synthgene's revenue model combines one-time sale of raw materials (cap analogs, nucleotides, enzymes, LNP components, GalNAc) with fee-for-service CRO contracts for custom mRNA and custom oligonucleotide synthesis, available in project-based and FTE formats. Pricing is not publicly disclosed and is handled through direct B2B sales via [email protected] and phone (400-885-0615). Distribution is direct enterprise sales supported by regional offices in Maryland (Areterna subsidiary, established 2023) and Singapore, plus participation in major industry exhibitions (CPHI China, I-RNA Summit, Nucleic Acid Summit). The primary customer segment is pharmaceutical and biotech companies developing mRNA vaccines, mRNA therapeutics including in vivo CAR-T, oligonucleotide drugs, and molecular diagnostics.
Shenji Bio firmographics
Firmographics- Name
- Shenji Bio
- Legal name
- Jiangsu Synthgene Biotechnology Co., Ltd.
- Website
- https://syngenebio.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Synthgene (Jiangsu Synthgene Biotechnology Co., Ltd.) is a China-based provider of nucleic acid raw materials and CRDMO services for mRNA therapeutics, oligonucleotide drugs, and molecular diagnostics, supplying GMP-grade inputs and integrated CRO services to pharmaceutical and biotech customers globally.
- Ownership category
- akta.pro rank
Shenji Bio industry classification
Industry- Product category
- Nucleic Acid Drug Raw Materials and CRDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)
- akta.pro secondary industries
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)
Keywords
Where Shenji Bio is headquartered
LocationHeadquarters
- HQ city
- Nanjing
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
Shenji Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Nucleic Acid Raw Materials: Sale of GMP-grade and research-grade raw materials including cap analogs, modified nucleotides, phosphoramidites, nucleosides, enzymes, LNP components, and GalNAc conjugates to pharmaceutical and biotech companies developing mRNA vaccines, oligonucleotide therapeutics, and molecular diagnostics.
- CRO Services (Custom mRNA and Oligonucleotide): Fee-for-service CRO contracts covering custom mRNA synthesis, oligonucleotide synthesis, and related technical development services. Services range from early R&D to commercial scale, with project-based and FTE (Full-Time Equivalent) collaboration models available.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Shenji Bio product offering
Product offeringCore offering
Shenji Bio (Synthgene) manufactures and supplies GMP- and research-grade nucleic acid drug raw materials, including cap analogs, modified nucleotides, phosphoramidites, nucleosides, enzymes, and LNP delivery components, for pharmaceutical and biotech companies developing mRNA vaccines, oligonucleotide therapeutics, and molecular diagnostics. The company also provides end-to-end CRDMO services covering custom mRNA synthesis and custom oligonucleotide synthesis, from sequence design through GMP production and quality release.
Product overview
Jiangsu Shenji Bio (Synthgene) is a global leader in RNA therapeutics raw materials and technology since 2018. The company offers an integrated portfolio of mRNA synthesis products (including enzymes, nucleotides, cap analogs, LNP systems, and stock mRNA), oligonucleotide synthesis materials (phosphoramidites, nucleosides, GalNAc conjugates), and diagnostic ingredients. The portfolio is supported by end-to-end CRO services for both custom mRNA development and custom oligonucleotide synthesis, covering the entire value chain from early research through commercial production. The company operates a 30,000 m2 GMP facility and holds over 100 patents, with products achieving over 80% market coverage in human mRNA vaccines and over 90% in animal mRNA vaccines.
Differentiator
Problem solved
Functional benefit
Products and services
- mRNA Raw Materials & Platform End-to-end mRNA synthesis solutions including IVT enzymes and buffers, modified nucleotides, cap analogs, stock mRNA, kits for mRNA, and LNP delivery systems for pharmaceutical and biotech companies developing mRNA vaccines and therapeutics.
- Oligo Synthesis Products Comprehensive oligonucleotide synthesis raw materials including phosphoramidites (DNA, 2'-O-Me, 2'-Fluoro, 2'-O-MOE, locked nucleic acid, and other modifications), nucleosides, GalNAc conjugates, enzymatic oligo synthesis reagents, succinates, and phosphorus reagents for ASO, siRNA, miRNA, and aptamer drug development.
- Diagnostics Products Molecular diagnostic raw materials including nucleotides and related compounds for diagnostic applications in pharmaceutical and biotech companies.
- Custom mRNA Services (mRNA CRO) Full-scope mRNA CRO services covering sequence design, mRNA preparation, LNP encapsulation, and quality testing, with GMP-grade raw materials from sequence design to product release. Targeted at pharmaceutical and biotech companies developing mRNA vaccines and therapeutics.
- Custom Oligonucleotide Services Customized oligonucleotide raw material services covering antisense oligonucleotides (ASO), siRNA, miRNA, aptamers, and other small nucleic acid drugs from early research to commercial production. Targeted at pharmaceutical and biotech companies developing oligonucleotide therapeutics.
- Ab-LNP Quality Control Services Nano-flow cytometry (nFCM) testing services for antibody-conjugated lipid nanoparticle quality control, including single-particle characterization, antibody density quantification, and targeting activity validation for in vivo CAR-T applications. Targeted at pharmaceutical and biotech companies developing in vivo CAR-T therapies.
Quantifiable outcome
- Over 80% market coverage in human mRNA vaccines and over 90% in animal mRNA vaccines
- +1 more outcomes
Companies that use Shenji Bio
Customer profileSegments1 record
Ideal customer profiles1 record
Shenji Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Shenji Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Xingrui Pharmaceuticals (星锐医药 / Starna Therapeutics)coreSynthgene is a strategic partner to Xingrui Pharmaceuticals (Starna Therapeutics), a clinical-stage mRNA drug developer founded in August 2021. Xingrui focuses on mRNA therapies with proprietary extra-hepatic delivery technology targeting lungs, intestines, and nervous system. Synthgene provides mRNA raw materials including IVT enzyme, cap analogs, modified nucleotides, and mRNA preparation and delivery solutions to support Xingrui's R&D. Synthgene's Ab-LNP QC services also support Xingrui's in vivo CAR-T pipeline development. Xingrui raised nearly $40M in Series B+ financing in May 2026.
Scale indicators6 records
Recent moves7 records
Expansion highlights14 records
Shenji Bio competitors and assessment
Company assessmentBroad incumbents
- Cytiva (Danaher): Cytiva supplies nucleic acid synthesis reagents, oligo synthesis platforms, and bioprocessing supplies that overlap with Synthgene's oligo raw materials and analytical offerings. Danaher-backed Cytiva is a significant established competitor in the upstream nucleic acid workflow.
- Agilent Technologies (CrossLab Biopharma): Agilent's Resolution Bioscience and nucleic acid solutions businesses provide oligonucleotide synthesis reagents and analytical tools that compete with Synthgene's oligo and diagnostics raw materials. As a large analytical instruments and life sciences tools company, it is a credible incumbent in adjacent product categories.
- Thermo Fisher Scientific: Thermo Fisher operates a global CDMO and life sciences tools business with mRNA manufacturing services, IVT enzymes, and nucleic acid raw materials that overlap with Synthgene's portfolio. Its Patheon CDMO and bioscience reagents divisions compete for the same large-pharma customers Synthgene targets.
- Merck KGaA (MilliporeSigma / SAFC): Merck's Life Science business offers a broad portfolio of mRNA manufacturing services, lipids, and nucleoside raw materials under the SAFC and Sigma brands, competing head-to-head with Synthgene across IVT enzymes, lipids, and CRDMO services. It is a top-tier global incumbent in the same end markets.
Direct peers
- WuXi STA (WuXi AppTec): WuXi STA is a leading China-based oligonucleotide and peptide CDMO with global scale, offering nucleic acid API manufacturing and CRDMO services that mirror Synthgene's custom oligo and mRNA service portfolio. It is the most relevant large Chinese competitor in the oligonucleotide CDMO space.
- GenScript Biotech: GenScript is a Chinese-rooted global life sciences company with a nucleic acid synthesis business (phosphoramidites, oligo synthesis, gene synthesis, mRNA services) that directly overlaps Synthgene's oligo and mRNA raw material offerings. Both target pharma/biotech customers developing oligonucleotide and mRNA therapeutics.
- TriLink BioTechnologies (Maravai LifeSciences): TriLink is the closest direct competitor as a leading global supplier of mRNA raw materials, cap analogs, modified nucleotides, and CleanCap capping technology, serving the same mRNA vaccines and therapeutics customer base as Synthgene. Both companies specialize in the upstream mRNA raw material toolkit that Synthgene also markets.
- Bioneer Corporation: Bioneer is a Korea-based nucleic acid-focused company offering oligonucleotide synthesis, mRNA production, and molecular diagnostics raw materials, directly comparable to Synthgene's phosphoramidite, nucleoside, and mRNA synthesis product lines. Both serve pharma/biotech and diagnostics customers across Asia.
- BioSpring (formerly BioSpring GmbH): BioSpring is a global CDMO specializing in oligonucleotides and nucleic acid APIs including phosphoramidites and modified nucleosides, directly comparable to Synthgene's custom oligonucleotide services and oligo raw material catalog. Both serve pharma and biotech customers developing ASO/siRNA therapeutics.
Regional players
- Asymchem Laboratories: Asymchem is a leading Chinese CDMO with growing oligonucleotide and nucleic acid manufacturing capabilities. It is comparable as a domestic Chinese CRDMO peer targeting both local and international pharma customers, though its primary focus remains small molecule APIs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Shenji Bio social profiles
Digital presenceShenji Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Shenji Bio leadership team
Management profileNumber of profiles
Shenji Bio subsidiaries and ownership
Company hierarchySubsidiaries1 record
Shenji Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Shenji Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Shenji Bio
What does Shenji Bio do?
Shenji Bio (Synthgene) manufactures and supplies GMP- and research-grade nucleic acid drug raw materials, including cap analogs, modified nucleotides, phosphoramidites, nucleosides, enzymes, and LNP delivery components, for pharmaceutical and biotech companies developing mRNA vaccines, oligonucleotide therapeutics, and molecular diagnostics. The company also provides end-to-end CRDMO services covering custom mRNA synthesis and custom oligonucleotide synthesis, from sequence design through GMP production and quality release.
Is Shenji Bio a public or private company?
Shenji Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Shenji Bio founded?
Shenji Bio was founded in 2018. It employs 51 to 100 people.
Where is Shenji Bio based?
Shenji Bio is headquartered in Nanjing, China, in the Asia region.
How does Shenji Bio make money?
Two revenue lines are on record. Nucleic Acid Raw Materials are the primary driver. The others are CRO Services (Custom mRNA and Oligonucleotide).
Who are Shenji Bio's main competitors?
Broad incumbents on record are Cytiva (Danaher), Agilent Technologies (CrossLab Biopharma), Thermo Fisher Scientific and Merck KGaA (MilliporeSigma / SAFC). Direct peers are WuXi STA (WuXi AppTec), GenScript Biotech, TriLink BioTechnologies (Maravai LifeSciences), Bioneer Corporation and BioSpring (formerly BioSpring GmbH). Asymchem Laboratories is listed as a regional player.
Does Shenji Bio have an API?
No public API is recorded for Shenji Bio.
What industry is Shenji Bio in?
Shenji Bio's product category is Nucleic Acid Drug Raw Materials and CRDMO Services. Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 325414 and its SIC code is 2836.